Drug Profile

SA 203

Alternative Names: SA-203

Latest Information Update: 28 Jul 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Sian Wuhan Medical Technology
Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

28 Jul 2026 No recent reports of development identified for preclinical development in Multiple-myeloma in China (Parenteral)
08 Sep 2022 Sian Wuhan Medical Technology plans to file an IND application for Multiple myeloma in H2 2024 (Sian Wuhan Medical Technology pipeline, September 2022)
08 Sep 2022 Sian Wuhan Medical Technology plans investigator initiated trial (IIT) for Multiple myeloma in H2 2023 (Sian Wuhan Medical Technology pipeline, September 2022)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com